ResMed Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 3.20B | 3.58B | 4.22B | 4.69B | 5.15B | 9.8% | |
| Cost of Revenue | (1.36B) | (1.55B) | (1.87B) | (2.03B) | (2.09B) | 3.0% | |
Gross Profit | 1.84B | 2.02B | 2.36B | 2.66B | 3.05B | 15.1% | |
| Operating Expenses | |||||||
| Research & Development | (225.28M) | (253.57M) | (287.64M) | (307.52M) | (331.28M) | 7.7% | |
| Selling, General & Administrative | (670.39M) | (739.37M) | (874.00M) | (917.14M) | (991.02M) | 8.1% | |
| Depreciation & Amortization | (191.52M) | (193.84M) | (196.52M) | (216.21M) | (235.81M) | 9.1% | |
Operating Income (EBIT) | 903.68M | 1.00B | 1.13B | 1.32B | 1.69B | 27.7% | |
| Non-Operating Items | |||||||
| Interest Income | 362.00K | — | — | — | — | — | |
| Interest Expense | (23.99M) | (22.31M) | (47.38M) | (45.71M) | (12.61M) | -72.4% | |
| Other Income/Expenses (Net) | -20.02M | -39.80M | -30.21M | -55.09M | -7.80M | -85.8% | |
Income Before Tax | 883.66M | 960.48M | 1.10B | 1.26B | 1.68B | 32.6% | |
| Income Tax Expense | (409.16M) | (181.05M) | (204.11M) | (243.85M) | (276.84M) | 13.5% | |
Net Income | 474.50M | 779.44M | 897.56M | 1.02B | 1.40B | 37.2% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $3 | $5 | $6 | $7 | $10 | 37.6% | |
| Weighted Avg Shares Outstanding | 145.31M | 146.07M | 146.76M | 147.02M | 146.72M | -0.2% | |
| Weighted Avg Shares Outstanding (Diluted) | 146.45M | 147.04M | 147.46M | 147.55M | 147.34M | -0.1% | |
EBITDA | 1.10B | 1.18B | 1.36B | 1.53B | 1.91B | 24.8% |
Explore RMD
RMD in the Healthcare
Large Cap